<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:25:11Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4766284" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4766284</identifier>
        <datestamp>2016-02-26</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4766284</article-id>
              <article-id pub-id-type="pmcid">PMC4766284</article-id>
              <article-id pub-id-type="pmc-uid">4766284</article-id>
              <article-id pub-id-type="pmid">26910762</article-id>
              <article-id pub-id-type="pmid">26910762</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0149087</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-15-04045</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Population Groupings</subject>
                    <subj-group>
                      <subject>Professions</subject>
                      <subj-group>
                        <subject>Sex Workers</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Research Design</subject>
                    <subj-group>
                      <subject>Cohort Studies</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Sexually Transmitted Diseases</subject>
                      <subj-group>
                        <subject>Chlamydia Infection</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical Microbiology</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Bacterial Pathogens</subject>
                          <subj-group>
                            <subject>Chlamydia Trachomatis</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Bacterial Pathogens</subject>
                          <subj-group>
                            <subject>Chlamydia Trachomatis</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Bacteria</subject>
                      <subj-group>
                        <subject>Chlamydia</subject>
                        <subj-group>
                          <subject>Chlamydia Trachomatis</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drugs</subject>
                      <subj-group>
                        <subject>Antimicrobials</subject>
                        <subj-group>
                          <subject>Antibiotics</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Microbial Control</subject>
                      <subj-group>
                        <subject>Antimicrobials</subject>
                        <subj-group>
                          <subject>Antibiotics</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Mathematics</subject>
                    <subj-group>
                      <subject>Statistics (Mathematics)</subject>
                      <subj-group>
                        <subject>Confidence Intervals</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Virology</subject>
                      <subj-group>
                        <subject>Co-Infections</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Natural History of Disease</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Apparently-Different Clearance Rates from Cohort Studies of <italic>Mycoplasma genitalium</italic> Are Consistent after Accounting for Incidence of Infection, Recurrent Infection, and Study Design</article-title>
                <alt-title alt-title-type="running-head"><italic>M</italic>. <italic>genitalium</italic> Incidence and Clearance</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smieszek</surname>
                    <given-names>Timo</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>White</surname>
                    <given-names>Peter J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>NIHR Health Protection Research Unit in Modelling Methodology and MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, United Kingdom</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Modelling and Economics Unit, Centre for Infectious Disease Surveillance and Control, Public Health England, London NW9 5EQ, United Kingdom</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Wilson</surname>
                    <given-names>Brenda A</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>University of Illinois at Urbana-Champaign, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <fn fn-type="con" id="contrib001">
                  <p>Analyzed the data: TS. Wrote the paper: TS PJW. Designed the model: TS PJW.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>timo.smieszek@phe.gov.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>2</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2016</year>
              </pub-date>
              <volume>11</volume>
              <issue>2</issue>
              <elocation-id>e0149087</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>1</month>
                  <year>2015</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>1</month>
                  <year>2016</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2016 Crown Copyright</copyright-statement>
                <copyright-year>2016</copyright-year>
                <copyright-holder>Crown Copyright</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>Reproduced with the permission of the Controller of Her Majesty’s Stationery Office/Queen’s Printer for Scotland and Public Health England. The Open Government License used by Crown Copyright permits anyone to copy, publish, distribute, transmit and adapt this work for commercial and/or non-commercial purposes, with proper attribution. To view this licence, visit <ext-link ext-link-type="uri" xlink:href="http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0149087.pdf"/>
              <abstract>
                <p><italic>Mycoplasma genitalium</italic> is a potentially major cause of urethritis, cervicitis, pelvic inflammatory disease, infertility, and increased HIV risk. A better understanding of its natural history is crucial to informing control policy. Two extensive cohort studies (students in London, UK; Ugandan sex workers) suggest very different clearance rates; we aimed to understand the reasons and obtain improved estimates by making maximal use of the data from the studies. As <italic>M</italic>. <italic>genitalium</italic> is a sexually-transmitted infectious disease, we developed a model for time-to-event analysis that incorporates the processes of (re)infection and clearance, and fitted to data from the two cohort studies to estimate incidence and clearance rates under different scenarios of sexual partnership dynamics and study design (including sample handling and associated test sensitivity). In the London students, the estimated clearance rate is 0.80p.a. (mean duration 15 months), with incidence 1.31%-3.93%p.a. Without adjusting for study design, corresponding estimates from the Ugandan data are 3.44p.a. (mean duration 3.5 months) and 58%p.a. Apparent differences in clearance rates are probably mostly due to lower testing sensitivity in the Uganda study due to differences in sample handling, with 'true' clearance rates being similar, and adjusted incidence in Uganda being 28%p.a. Some differences are perhaps due to the sex workers having more-frequent antibiotic treatment, whilst reinfection within ongoing sexual partnerships might have caused some of the apparently-persistent infection in the London students. More information on partnership dynamics would inform more accurate estimates of natural-history parameters. Detailed studies in men are also required.</p>
              </abstract>
              <funding-group>
                <funding-statement>This work was supported by the UK National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Modelling Methodology at Imperial College London in partnership with Public Health England (PHE) [grant number HPRU-2012-10080;<ext-link ext-link-type="uri" xlink:href="http://www.nihr.ac.uk">http://www.nihr.ac.uk</ext-link>] and by the UK Medical Research Council for Centre funding [grant number MR/K010174/1; <ext-link ext-link-type="uri" xlink:href="http://www.mrc.ac.uk">http://www.mrc.ac.uk</ext-link>]. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the MRC, NHS, the NIHR, the Department of Health, or Public Health England.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="8"/>
                <table-count count="0"/>
                <page-count count="18"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the paper.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the paper.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>Sexually-transmitted <italic>Mycoplasma genitalium</italic> has recently gained increasing attention as a major cause of urethritis [<xref rid="pone.0149087.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0149087.ref003" ref-type="bibr">3</xref>], cervicitis [<xref rid="pone.0149087.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0149087.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0149087.ref004" ref-type="bibr">4</xref>], pelvic inflammatory disease (PID) [<xref rid="pone.0149087.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0149087.ref002" ref-type="bibr">2</xref>], infertility [<xref rid="pone.0149087.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0149087.ref005" ref-type="bibr">5</xref>], and increased HIV risk [<xref rid="pone.0149087.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0149087.ref006" ref-type="bibr">6</xref>]. Currently testing is not routinely done in, e.g., UK or USA, and there is only limited testing in Australia [<xref rid="pone.0149087.ref007" ref-type="bibr">7</xref>–<xref rid="pone.0149087.ref010" ref-type="bibr">10</xref>], so disease would be usually diagnosed syndromically, e.g., non-chlamydial non-gonococcal urethritis. Furthermore, frequent treatment failures [<xref rid="pone.0149087.ref010" ref-type="bibr">10</xref>–<xref rid="pone.0149087.ref012" ref-type="bibr">12</xref>] and high prevalence of macrolide-resistant strains [<xref rid="pone.0149087.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0149087.ref013" ref-type="bibr">13</xref>–<xref rid="pone.0149087.ref015" ref-type="bibr">15</xref>] indicate suboptimal infection management and treatment [<xref rid="pone.0149087.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0149087.ref017" ref-type="bibr">17</xref>].</p>
              <p><italic>M</italic>. <italic>genitalium</italic>’s impact on sexual and reproductive health necessitates a greater understanding of its natural history, including duration of untreated infection, proportion of infections that are symptomatic, and infectivity, to inform decisions regarding if and how public health interventions should be implemented. There have been calls for such interventions for <italic>M</italic>. <italic>genitalium</italic> [<xref rid="pone.0149087.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0149087.ref017" ref-type="bibr">17</xref>], but we note that continued uncertainty regarding the natural history of <italic>Chlamydia trachomatis</italic> [<xref rid="pone.0149087.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0149087.ref019" ref-type="bibr">19</xref>] means that the (cost-)effectiveness of screening remains unknown, and the interventions now in place complicate further study.</p>
              <p>Two extensive cohort studies [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>–<xref rid="pone.0149087.ref023" ref-type="bibr">23</xref>] have examined aspects of <italic>M</italic>. <italic>genitalium</italic>’s natural history in women, including rates of clearance of infection; intriguingly, the clearance rates were apparently very different. As cohort studies are difficult, expensive and time-consuming to conduct, it is important to obtain the maximum information from them.</p>
              <p>In this paper we obtain refined parameter estimates through using an analytic approach that synthesizes additional evidence reported by the studies. In particular, we take into account that <italic>M</italic>. <italic>genitalium</italic> is a sexually-transmitted infection, and that members of the study cohort might acquire infection during the study, and that that those infected at enrolment might recover and become infected again by the time of follow-up, which would not be distinguishable from a persistent infection.</p>
              <p>Furthermore, we aim to gain insight into the reasons for the differences reported by the studies, including potential reinfection within stable sexual partnerships (in a prolonged partnership if one partner is infected then there is an elevated risk that both partners will be infected, so that if one partner recovers during the partnership, there is an elevated risk of the person becoming infected again rapidly), to determine if the differences are likely to be due to differences in study design or due to ‘real’ biological or behavioral differences. Finally, we make recommendations for improving future studies to inform decisions regarding if and how public-health decision-making regarding if and how interventions should be implemented.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Materials and Methods</title>
              <p>We estimated the clearance rates from data that were collected in two cohort studies, one of students in London, UK, [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>] and the other of Ugandan sex workers [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>–<xref rid="pone.0149087.ref023" ref-type="bibr">23</xref>], using models that include acquisition of infection, including recurrent infection, as well as recovery. We further analyzed how two factors, (i) duration of sexual partnerships and (ii) test sensitivity, influence parameter estimates.</p>
              <p>In this paper, we use “recurrent infection” to refer to an infection acquired after clearance of a previous infection, and “reinfection” as a recurrent infection that is acquired within a stable sexual partnership.</p>
              <sec id="sec003">
                <title>Data</title>
                <sec id="sec004">
                  <title>Female students, London, UK</title>
                  <p>Oakeshott et al. [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>] conducted a combined <italic>C</italic>. <italic>trachomatis</italic> and <italic>M</italic>. <italic>genitalium</italic> cohort study of female students in London (mean age: 21 years). Participants completed a sexual-behavior questionnaire at baseline and provided self-taken vaginal swabs at baseline and follow-up, 11–32 months later. Specimens were stored at -80°C until tested for <italic>M</italic>. <italic>genitalium</italic> by PCR. <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref> summarizes results.</p>
                  <fig id="pone.0149087.g001" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g001</object-id>
                    <label>Fig 1</label>
                    <caption>
                      <title>Flow charts of two cohort studies.</title>
                      <p>(A) Oakeshott et al. [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>]; numbers 1 to 6 are data items that are referred-to in the text; follow-up was after 12–21 months (median 16 months) for items 2 and 5 (grey), and after 11–32 months (median 16 months) for items 3 and 6; arrows exiting boxes indicate numbers of participants lost. (B) Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>]; numbers of <italic>M</italic>. <italic>genitalium</italic>-positive and -negative participants at baseline, as well as numbers of participants consistently <italic>M</italic>. <italic>genitalium</italic>-positive at consecutive time points, and numbers testing negative at each time point, who were not considered further in the analysis.</p>
                    </caption>
                    <graphic xlink:href="pone.0149087.g001"/>
                  </fig>
                </sec>
                <sec id="sec005">
                  <title>Female sex workers, Kampala, Uganda</title>
                  <p>Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>–<xref rid="pone.0149087.ref023" ref-type="bibr">23</xref>] conducted a cohort study of women working in the sex industry in Kampala, Uganda (median age: 26 years [<xref rid="pone.0149087.ref023" ref-type="bibr">23</xref>]). Participants were asked to visit a project clinic at 3-month intervals, where they were repeatedly interviewed and where specimens were collected to be tested for HIV, HSV2, syphilis, gonorrhea, chlamydia, <italic>T</italic>. <italic>vaginalis</italic>, <italic>Candida</italic>, and <italic>M</italic>. <italic>genitalium</italic>. <italic>M</italic>. <italic>genitalium</italic> specimens were taken by project clinic staff using endocervical swabs. Those reporting STI symptoms or testing positive for any STI other than <italic>M</italic>. <italic>genitalium</italic> (which was tested for ex-post) were treated promptly. Specimens were brought to a laboratory within 12 hours and stored at -20°C until tested for <italic>M</italic>. <italic>genitalium</italic> by PCR. <xref ref-type="fig" rid="pone.0149087.g001">Fig 1B</xref> summarizes results.</p>
                  <p>More-detailed information about the study protocols is available in the related, freely accessible publications [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>–<xref rid="pone.0149087.ref023" ref-type="bibr">23</xref>].</p>
                </sec>
              </sec>
              <sec id="sec006">
                <title>Simulation model calibrated to the London-student data</title>
                <p>We represent individuals’ <italic>M</italic>. <italic>genitalium</italic> infection status with a <bold><italic>S</italic></bold><italic>usceptible</italic>-<bold><italic>I</italic></bold><italic>nfected</italic>-<bold><italic>S</italic></bold><italic>usceptible</italic>-type model, in which individuals are in one of two discrete states: <italic>Susceptible</italic> (<italic>S</italic>, uninfected) and Infected (<italic>I</italic>), as shown in <xref ref-type="fig" rid="pone.0149087.g002">Fig 2A</xref>. These are the same states as used in a typical statistical survival (time-to-event) analysis; however, our model has the important difference that we also allow for individuals to become (re-)infected over time. We assume the prevalence of <italic>M</italic>. <italic>genitalium</italic>-positive individuals is stable over time and, hence, also the force of infection or incidence rate (<italic>λ</italic>) is stable.</p>
                <fig id="pone.0149087.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Schemata of model components.</title>
                    <p>(A) Schema of London-student model. <italic>S</italic>: Susceptible state; <italic>I</italic>: Infected state; <italic>λ</italic><sub><italic>low</italic></sub>: incidence rate of low-risk group; <italic>λ</italic><sub><italic>high</italic></sub>: incidence rate of high-risk group; <italic>γ</italic>: recovery rate. (B) Schema of the succession of Infected and Susceptible states. <italic>S</italic>: Susceptible state; <italic>I</italic>: Infected state; <italic>t</italic><sub>1</sub>: time at baseline; <italic>t</italic><sub>2</sub>: time at follow-up; <italic>T</italic><sub><italic>F</italic></sub>: time to follow-up; in this example, the individual was <italic>Infected</italic> at baseline and, again, at follow-up.</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g002"/>
                </fig>
                <p>The transition <italic>S</italic> → <italic>I</italic> occurs with rate <italic>λ</italic><sub><italic>low</italic></sub> for the London students with &lt;2 partners in the previous year (low-risk group) and with rate <italic>λ</italic><sub><italic>high</italic></sub> for those with ≥2 partners (high-risk group), which are the groups reported by Oakeshott et al [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>]. The transition <italic>I</italic> → <italic>S</italic> occurs with rate <italic>γ</italic> for all individuals. Hence, the infected period <italic>T</italic><sub><italic>I</italic></sub> has a mean of <italic>γ</italic><sup>-1</sup> and it is exponentially distributed with <italic>exp</italic>(<italic>γ</italic>). The susceptible periods <italic>T</italic><sub><italic>S</italic></sub> also follow exponential distributions with parameters <italic>λ</italic><sub><italic>low</italic></sub> and <italic>λ</italic><sub><italic>high</italic></sub>, respectively. Individuals cycle between states <italic>S</italic> and <italic>I</italic>.</p>
                <p>Our model aims at producing the overall best fit (maximum-likelihood) to six data items as in <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref>: the baseline prevalence in (1) the high-risk and (4) the low-risk group; the proportion of the initially infected individuals who were also infected at follow-up for (2) the high-risk and (5) the low-risk group; the proportion of those individuals whose initial <italic>M</italic>. <italic>genitalium</italic> test was negative that had a positive follow-up test for (3) the high-risk and (6) the low-risk group.</p>
                <sec id="sec007">
                  <title>Prevalence</title>
                  <p>The probability <italic>P</italic><sub>I,i</sub> that any given individual <italic>i</italic> is <italic>Infected</italic> at any time <italic>t</italic><sub><italic>x</italic></sub> is given by <italic>λ</italic>/(<italic>λ</italic>+<italic>γ</italic>), with respective indices for low- and high-risk groups. Given the information about the prevalence in the low- and high-risk group (see <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref>), the log-likelihood functions are defined as
<disp-formula id="pone.0149087.e001"><alternatives><graphic xlink:href="pone.0149087.e001.jpg" id="pone.0149087.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mo>+</mml:mo></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mo>−</mml:mo></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
<disp-formula id="pone.0149087.e002"><alternatives><graphic xlink:href="pone.0149087.e002.jpg" id="pone.0149087.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mo>+</mml:mo></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mo>−</mml:mo></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula>
where <italic>L</italic><sub>+</sub> is the set of all study participants <italic>i</italic> who belonged to the low-risk group and tested positive for <italic>M</italic>. <italic>genitalium</italic> at baseline; <italic>L</italic><sub>−</sub> is the set of all study participants <italic>j</italic> who belonged to the low-risk group, but had a negative initial test result; <italic>H</italic><sub>+</sub> and <italic>H</italic><sub>−</sub> are the respective sets for the high-risk group.</p>
                </sec>
                <sec id="sec008">
                  <title>Baseline versus follow-up measurements</title>
                  <p>The data in <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref> provide information about the infection status of all study participants at the baseline measurement, but also of many study participants at follow-up. The probability <inline-formula id="pone.0149087.e003"><alternatives><graphic xlink:href="pone.0149087.e003.jpg" id="pone.0149087.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> that individual <italic>i</italic> is <italic>Infected</italic> at time of follow-up, <italic>t</italic><sub>2</sub>, depends on the infection status at baseline (i.e., at <italic>t</italic><sub>1</sub>), the duration of the time period between baseline and follow-up measurement, <italic>T</italic><sub><italic>F</italic></sub>, as well as on <italic>λ</italic><sub><italic>low</italic></sub>, <italic>λ</italic><sub><italic>high</italic></sub> and <italic>γ</italic>.</p>
                  <p>Time to follow-up, <italic>T</italic><sub><italic>F</italic></sub>, varied between study participants, and only the minimum, the maximum, and the median, <italic>μ</italic><sub>1/2</sub>, are known for both the low- and the high-risk group (see <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref>). For any given individual <italic>i</italic>, <italic>T</italic><sub><italic>F</italic></sub> is within interval [min, <italic>μ</italic><sub>1/2</sub>] with a probability of 50% and within interval [<italic>μ</italic><sub>1/2</sub>, max] also with a probability of 50%. In absence of further information about the distribution, we assume that <italic>T</italic><sub><italic>F</italic></sub> follows a uniform distribution within each interval.</p>
                  <p>We determined the mean probability <italic>P</italic><sub><italic>I</italic></sub> that an individual is <italic>Infected</italic> at follow-up–given the infection status at baseline and whether the individual belongs to the high- or low-risk group–stochastically, by cycling through <italic>Infected</italic> and <italic>Susceptible</italic> states until <italic>t</italic><sub>2</sub> is passed (<xref ref-type="fig" rid="pone.0149087.g002">Fig 2B</xref>). The infection status at time <italic>t</italic><sub>2</sub> determines the infection status at follow-up. For each set of parameters, the estimate of <italic>P</italic><sub><italic>I</italic></sub> is based on at least 10<sup>6</sup> realizations, and in areas of the parameter space with a high likelihood, we used up to 10<sup>7</sup> realizations.</p>
                  <p>The likelihood functions <italic>L</italic><sub><italic>baseline+</italic>,<italic>low</italic></sub>, <italic>L</italic><sub><italic>baseline+</italic>,<italic>high</italic></sub>, <italic>L</italic><sub><italic>baseline–</italic>,<italic>low</italic></sub>, and <italic>L</italic><sub><italic>baseline–</italic>,<italic>high</italic></sub> are defined analogous to Eqs <xref ref-type="disp-formula" rid="pone.0149087.e001">1</xref> and <xref ref-type="disp-formula" rid="pone.0149087.e002">2</xref>, using the mean probability of being infected at <italic>t</italic><sub>2</sub> as described above.</p>
                </sec>
                <sec id="sec009">
                  <title>Combined log-likelihood function and parameter space</title>
                  <p>The combined log-likelihood is defined as
<disp-formula id="pone.0149087.e004"><alternatives><graphic xlink:href="pone.0149087.e004.jpg" id="pone.0149087.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:mi>L</mml:mi><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="13em"/><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="13em"/><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="13em"/><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="13em"/><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mo>−</mml:mo><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="13em"/><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mo>−</mml:mo><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(3)</label></disp-formula></p>
                  <p>We established the likelihood landscape for a parameter space defined by vector <inline-formula id="pone.0149087.e005"><alternatives><graphic xlink:href="pone.0149087.e005.jpg" id="pone.0149087.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> for the intervals <italic>λ</italic><sub><italic>low</italic></sub> in [0.0050, 0.0500] with a step width of 10<sup>−4</sup>, <italic>γ</italic> in [0.01, 4.00] with a step width of 0.01, and <italic>λ</italic><sub><italic>high</italic></sub>/<italic>λ</italic><sub><italic>low</italic></sub> in [2.5, 3.5] with a step width of 0.1.</p>
                  <p>The parameter combination with the highest overall log-likelihood value represents with maximal likelihood the ‘true’ recovery and incidence rates, given that the underlying model is a good representation of the ‘real’ infection and clearance processes. We refer to this parameter combination as maximum likelihood estimate (MLE).</p>
                </sec>
                <sec id="sec010">
                  <title>Sensitivity analyses</title>
                  <p>Having incomplete information means that we have to make some assumptions, e.g., the exact distribution of the time to follow-up. We examined scenarios to analyse how two key assumptions affect our results.</p>
                  <p><bold>Time to follow-up:</bold> We assume that the time lag between the baseline and the follow-up measurements is uniformly distributed between the minimum and median as well as between the median and the maximum. For the sensitivity analysis, we define two other, extreme scenarios: one scenario, where <italic>T</italic><sub><italic>F</italic></sub> = min with a probability of 50% and <italic>T</italic><sub><italic>F</italic></sub> = <italic>μ</italic><sub>1/2</sub> with probability 50%; and an alternative scenario, where <italic>T</italic><sub><italic>F</italic></sub> = <italic>μ</italic><sub>1/2</sub> or <italic>T</italic><sub><italic>F</italic></sub> = max, both with a probability of 50%.</p>
                  <p><bold>Partnership duration:</bold> We do not have any information about partnership durations, and, hence, our model does not incorporate the effects of stable sexual partnerships on infection transmission dynamics. In monogamous, stable partnerships, the risk of acquiring infections is either considerably elevated above the population average (if the partner is infected) [<xref rid="pone.0149087.ref024" ref-type="bibr">24</xref>] or non-existent (if the partner is not infected), compared to a situation with frequent casual partnerships (and no stable partnership). To assess the potential bias introduced by our assumption, we analyze how our results would differ, if we were to assume that all individuals of the low-risk group with two consecutive positive tests were in a stable partnership and became reinfected within this partnership; in our modeling framework, these cases could not contribute to the estimation of the recovery rate and so are excluded in the sensitivity analysis.</p>
                </sec>
              </sec>
              <sec id="sec011">
                <title>Model calibrated to Ugandan sex workers, including test sensitivity</title>
                <p>In the study of sex workers in Uganda [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>–<xref rid="pone.0149087.ref023" ref-type="bibr">23</xref>], sample-storage conditions and the type of specimens collected might have reduced sensitivity of testing relative to the London study [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>], and we tested if this might be an explanation for the results having been different. We model both (i) the clearance of and recurrent infection with <italic>M</italic>. <italic>genitalium</italic> among the Ugandan sex-worker population–analogous to the model of the London students–and (ii) the detection of infection, allowing for false-negative test results. No information about differing levels of sexual activity are available and, hence, no further subdivision into risk groups is performed.</p>
                <sec id="sec012">
                  <title>Prevalence</title>
                  <p>The observed prevalence from the participants’ first clinic visit is modeled–analogous to the London student study–as
<disp-formula id="pone.0149087.e006"><alternatives><graphic xlink:href="pone.0149087.e006.jpg" id="pone.0149087.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi>P</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfrac><mml:mi>λ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mi>λ</mml:mi></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>I</mml:mi></mml:munder><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:msub><mml:mi>P</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>S</mml:mi></mml:munder><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(4)</label></disp-formula>
where <italic>P</italic><sub><italic>sens</italic></sub> denotes the test sensitivity and can take any value between 0 (i.e., the test does not detect any of the truly infected cases) and 1 (i.e., the test detects all infected cases and so produces no false-negative results). Set <italic>I</italic> includes all study participants who were infected as the first clinic visit, set <italic>S</italic> includes the complement.</p>
                </sec>
                <sec id="sec013">
                  <title>Clearance</title>
                  <p>We model the expected distribution of the clinic visit at which the first negative test result occurred. A negative test result can be due to clearance (analogous to the London student model, see <xref ref-type="fig" rid="pone.0149087.g002">Fig 2B</xref>), or due to a false-negative test results. We model clearance and recurrent infection as for the London students, but record false-negative results with probability 1–<italic>P</italic><sub><italic>sens</italic></sub> for every clinic visit where the simulated individual is infected.</p>
                  <p>We repeated this procedure 5∙10<sup>6</sup> times and obtained stochastic estimates for the probabilities <italic>P</italic><sub>2</sub>, <italic>P</italic><sub>3</sub>, <italic>P</italic><sub>4</sub> and <italic>P</italic><sub>5</sub> that any given individual had her first negative test result at the respective clinic visit, as well as for the probability <italic>P</italic><sub><italic>no</italic></sub> that an individual didn’t have a negative result throughout the entire duration of the study (i.e., consistently tested positive). This allows us to define a log-likelihood function for the clearance of <italic>M</italic>. <italic>genitalium</italic>:
<disp-formula id="pone.0149087.e007"><alternatives><graphic xlink:href="pone.0149087.e007.jpg" id="pone.0149087.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:mrow><mml:mi>ln</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo mathvariant="bold">[</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mi>λ</mml:mi></mml:mtd><mml:mtd><mml:mi>γ</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo mathvariant="bold">]</mml:mo></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mn>65</mml:mn></mml:mrow></mml:munder><mml:mrow><mml:mi>ln</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mo>…</mml:mo><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mn>8</mml:mn></mml:munder><mml:mrow><mml:mi>ln</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula></p>
                </sec>
                <sec id="sec014">
                  <title>Consistency with London-student data</title>
                  <p>We tested if we could construct a model (overall log-likelihood functions was the sum of Eqs <xref ref-type="disp-formula" rid="pone.0149087.e006">4</xref> and <xref ref-type="disp-formula" rid="pone.0149087.e007">5</xref>) using recovery rate estimates from the London-student data and which is consistent with the Ugandan sex-worker data (α level of 0.05) if we vary the relative testing sensitivity in the Ugandan study to obtain the best fit to the empirical data.</p>
                  <p>We tested consistency using the following recovery rates from the London-student data:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p><italic>γ</italic>, the maximum-likelihood estimate (MLE);</p>
                    </list-item>
                    <list-item>
                      <p><italic>γ</italic><sub><italic>UCL</italic></sub>, the upper bound of the 95% confidence interval (CI) of the MLE;</p>
                    </list-item>
                    <list-item>
                      <p><italic>γ</italic><sub><italic>max</italic></sub>, the highest possible recovery rate, for which the outcomes of the London-student model are not significantly different from the London-student data (<italic>α</italic> level of 0.05);</p>
                    </list-item>
                    <list-item>
                      <p><italic>γ</italic><sub><italic>stable</italic>,<italic>max</italic></sub>, the highest possible recovery rate, when we assumed that all low-risk students, who were positive at baseline and follow-up, were in stable partnerships.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="sec015">
                  <title>Recurrent infection in Ugandan sex workers</title>
                  <p>We further analyzed which of the parameter sets (consisting of incidence and recovery rate as well as sensitivity) are consistent with apparently-recurrent infections that were observed in the Ugandan sex workers: 39% of the women who seemed to have cleared infection (i.e. tested negative after previously testing positive) tested positive again within 3 to 6 months [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>].</p>
                  <p>We used our model of the Ugandan sex workers to determine how likely a sequence of positive-negative-positive results in successive tests is for the 109 women who had a negative test result at the 2nd, 3rd, or 4th clinic visit. We then used a binomial test (two-sided) to determine if the parameter-model combination is consistent with the observed 39% recurrent infections.</p>
                </sec>
              </sec>
              <sec id="sec016">
                <title>Confidence intervals and consistency</title>
                <sec id="sec017">
                  <title>Confidence intervals for MLEs</title>
                  <p>We determined 95% confidence intervals for all MLEs with likelihood-ratio tests. The confidence interval is, hence, defined by
<disp-formula id="pone.0149087.e008"><alternatives><graphic xlink:href="pone.0149087.e008.jpg" id="pone.0149087.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:mi>L</mml:mi><mml:mrow><mml:mo mathvariant="bold">(</mml:mo><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mtext>ln</mml:mtext><mml:mspace width="0.15em"/><mml:mi>L</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi>θ</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi mathvariant="bold">data</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>≤</mml:mo><mml:mi>c</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives><label>(6)</label></disp-formula>
where <inline-formula id="pone.0149087.e009"><alternatives><graphic xlink:href="pone.0149087.e009.jpg" id="pone.0149087.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></alternatives></inline-formula> is the MLE, <italic>θ</italic> is any other parameter vector, and <italic>crit</italic>. is a critical value. Since the likelihood-ratio statistic follows approximately the <italic>χ</italic><sup>2</sup> distribution, we obtain the critical value for an <italic>α</italic>-level of 0.05 from this distribution.</p>
                </sec>
                <sec id="sec018">
                  <title>Consistency between data and model</title>
                  <p>For all data items where the outcome was dichotomous (i.e., <italic>Infected</italic> versus <italic>Susceptible</italic>), we used a binomial test (two-sided) to determine if a specific parameter-model combination could possibly produce the observed data. If a parameter set produces results that are significantly different (<italic>α</italic>-level of 0.05) from any observed data item, we deem the respective parameter set as inconsistent with the data.</p>
                  <p>One data item from the Ugandan sex worker study–the clinic visit when the participant had her first negative test result, if at all–is represented as a contingency table. Statistical difference between the observed data and the expected model outcome was evaluated with the G-test (<italic>α</italic>-level of 0.05).</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="sec019">
              <title>Results</title>
              <sec id="sec020">
                <title>Overview of results</title>
                <p>We present expected infection durations corresponding to the various estimates of clearance rate (from the two studies under different assumptions) in <xref ref-type="fig" rid="pone.0149087.g003">Fig 3</xref>, and describe the details of the analyses below.</p>
                <fig id="pone.0149087.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Duration of infection.</title>
                    <p>Proportions of individuals remaining infected over time are shown for the various estimates of clearance rates, <italic>γ</italic><sub><italic>students</italic></sub> = 0.80p.a., <italic>γ</italic><sub><italic>UCL</italic></sub> = 1.34p.a., <italic>γ</italic><sub><italic>max</italic></sub> = 1.84p.a., <italic>γ</italic><sub><italic>stable</italic>,<italic>max</italic></sub> = 2.06p.a. (all based on the London-student data), and <italic>γ</italic><sub><italic>sexwork</italic></sub> = 3.44p.a. (based on the Ugandan sex-worker data); vertical lines mark time points when, on average, half of the initially infected individuals will have cleared the infection, depending on the respective recovery rate.</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g003"/>
                </fig>
              </sec>
              <sec id="sec021">
                <title>Parameter estimates for the London-student data</title>
                <p>The best-fitting parameter combination, using all the available data items, is a recovery rate (<italic>γ</italic>) of 0.80p.a. (95% CI: 0.45–1.34; mean duration of infection of 15 months), with corresponding incidence rates, <italic>λ</italic><sub><italic>low</italic></sub> = 1.31%p.a. (95% CI: 0.75%-2.25%) and <italic>λ</italic><sub><italic>high</italic></sub> = 3.93%p.a. (95% CI: 2.25%-6.75%), since the most likely <italic>λ</italic><sub><italic>high</italic></sub>/<italic>λ</italic><sub><italic>low</italic></sub> is 3.0 (Figs <xref ref-type="fig" rid="pone.0149087.g004">4</xref> and <xref ref-type="fig" rid="pone.0149087.g005">5</xref>). For comparison, Oakeshott et al.’s [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>] estimated incidence was 0.9% (95% CI: 0.5%-1.6%). However, a very wide range of parameter values are compatible with (i.e., not significantly different from) the empirical data (area within red contour lines, <xref ref-type="fig" rid="pone.0149087.g005">Fig 5</xref>). The maximal recovery rate (<italic>γ</italic><sub><italic>max</italic></sub>) for which the model outcomes are not significantly different from the empirical data is 1.84p.a. (mean duration ~6.5 months).</p>
                <fig id="pone.0149087.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Likelihood landscapes by data item, London students.</title>
                    <p>Upper and lower rows of the panels correspond, respectively, to the high-risk group (≥2 partners in the preceding year at baseline) and low-risk group (&lt;2 partners); columns of the panels correspond to the prevalence at baseline, the proportion of positive tests at follow-up among the initially <italic>M</italic>. <italic>genitalium</italic>-positive participants, and the proportion of positive test at follow-up among the initially negative participants. Numbering corresponds to <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref>; black dots: overall maximum-likelihood estimate (MLE) for the recovery (<italic>γ</italic> = 0.80p.a.) and the incidence rates (<italic>λ</italic><sub><italic>low</italic></sub> = 1.31%p.a.); the ratio <italic>λ</italic><sub><italic>high</italic></sub>/<italic>λ</italic><sub><italic>low</italic></sub> was fixed at the MLE of 3.0; thin, black contours: equal likelihood; colored areas: white indicates maximum likelihood, red indicates low likelihood; thick, red contours: parameter area where the model is consistent with the empirical data (<italic>α</italic>&lt;0.05).</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g004"/>
                </fig>
                <fig id="pone.0149087.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Recovery rate vs. incidence rate, maximum-likelihood estimate and plausible parameter range, London students.</title>
                    <p>Black dot: maximum-likelihood estimate (MLE) for the recovery rate (<italic>γ</italic> = 0.80p.a.) and the incidence rate (<italic>λ</italic><sub><italic>low</italic></sub> = 1.31%p.a.); the ratio <italic>λ</italic><sub><italic>high</italic></sub>/<italic>λ</italic><sub><italic>low</italic></sub> was fixed at the MLE of 3.0; thin, black contours: equal likelihood; combined likelihood for all six data items (see <xref ref-type="fig" rid="pone.0149087.g004">Fig 4</xref>); colored areas: white indicates maximum likelihood, red indicates low likelihood; thick, dashed, blue contour: 95% CI of the MLE; thick, red contour: parameter area where the model is consistent with the empirical data (<italic>α</italic>&lt;0.05).</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g005"/>
                </fig>
                <p><xref ref-type="fig" rid="pone.0149087.g004">Fig 4</xref> shows the likelihood landscape for all six data items from <xref ref-type="fig" rid="pone.0149087.g001">Fig 1A</xref> separately. The parameters <italic>λ</italic> and <italic>γ</italic> are tightly linked in the cases of prevalence (1 and 4) and infection of initially uninfected participants (3 and 6): high <italic>λ</italic> requires high <italic>γ</italic> to reproduce the data; low <italic>λ</italic> requires low <italic>γ</italic>. The slope of the most likely parameter range is steeper for items 1 and 4 than for items 3 and 6. The MLE for <italic>γ</italic> is predominantly driven by the data on the number of initially <italic>M</italic>. <italic>genitalium</italic>-positive participants who were still positive at the time of the follow-up (items 2 and 5).</p>
                <p>The estimates are rather insensitive to changes in the assumed distribution of times to follow-up. In the scenario using the longest times that were consistent with the reported minimum, maximum, and median yields <italic>γ</italic><sub><italic>h</italic></sub> = 0.75p.a. (95% CI: 0.44–1.23) and <italic>λ</italic><sub><italic>h</italic>,<italic>low</italic></sub> = 1.24%p.a. (95% CI: 0.74%-2.10%). In the scenario using the shortest times, <italic>γ</italic><sub><italic>l</italic></sub> = 0.86p.a. (95% CI: 0.51–1.5) and <italic>λ</italic><sub><italic>l</italic>,<italic>low</italic></sub> = 1.46%p.a. (95% CI: 0.86%-2.52%).</p>
                <p>If we assume that all low-risk individuals who were positive both at baseline and follow-up were potentially reinfected within a stable partnership, and therefore removed from the analysis, then the best estimate for the recovery rate shifts to <italic>γ</italic><sub><italic>stable</italic></sub> = 1.34p.a. (95% CI: 0.66–2.18) with <italic>λ</italic><sub><italic>stable</italic>,<italic>low</italic></sub> = 2.17%p.a. (95% CI: 1.08%-3.00%), but the highest possible recovery rate that was consistent with all six data items was only <italic>γ</italic><sub><italic>stable</italic>,<italic>max</italic></sub> = 2.06p.a., which corresponds to a mean duration of infection of ~5.8 months.</p>
              </sec>
              <sec id="sec022">
                <title>Clearance of <italic>M</italic>. <italic>genitalium</italic> infection in Ugandan sex workers</title>
                <p>Clearance of <italic>M</italic>. <italic>genitalium</italic> in the Ugandan sex-worker cohort appeared to be relatively fast, compared with to the London-student cohort: a simple analysis, fitting an exponential curve to the five data points suggests a recovery rate <italic>γ</italic> = 3.14p.a., corresponding to a mean duration of infection of ~3.8 months.</p>
                <p><xref ref-type="fig" rid="pone.0149087.g006">Fig 6</xref> shows the results of a model fit, where we aimed at producing the best fit to the initial prevalence and the apparent clearance as in <xref ref-type="fig" rid="pone.0149087.g001">Fig 1B</xref>. The best-fitting parameter combination is <italic>γ</italic> = 3.44p.a. (95% CI: 2.78–4.29); <italic>λ</italic> = 58%p.a. (95% CI: 44%-78%). Neither the confidence intervals, nor the plausible parameter ranges for the London-student (<italic>γ</italic><sub><italic>max</italic></sub> = 1.84p.a.) and the Ugandan sex-worker (<italic>γ</italic><sub><italic>min</italic></sub> = 2.67p.a.) models overlap, suggesting that additional factors need to be incorporated in the model to explain both datasets with one common recovery rate.</p>
                <fig id="pone.0149087.g006" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g006</object-id>
                  <label>Fig 6</label>
                  <caption>
                    <title>Recovery rate vs. incidence rate, maximum-likelihood estimate and plausible parameter range, Ugandan sex workers.</title>
                    <p>Black dot: maximum-likelihood estimate (MLE) for the recovery rate (<italic>γ</italic> = 3.44p.a.) and the incidence rate (<italic>λ</italic><sub><italic>low</italic></sub> = 58%p.a.); thin, black contours: equal likelihood; colored areas: white indicates maximum likelihood, red indicated low likelihood; thick, dashed, blue contour: 95% CI of the MLE; thick, red contour: parameter area where the model is consistent with the empirical data (<italic>α</italic>&lt;0.05); vertical lines: estimates from London-student data; dotted: maximum-likelihood estimate (<italic>γ</italic> = 0.80p.a.); short-dashed: highest plausible estimate (<italic>γ</italic><sub><italic>max</italic></sub> = 1.84p.a.); long-dashed: highest plausible with stable partnership assumption (<italic>γ</italic><sub><italic>stable</italic>,<italic>max</italic></sub> = 2.06p.a.).</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g006"/>
                </fig>
                <p>Since one explanation for the apparent differences between the studies in clearing <italic>M</italic>. <italic>genitalium</italic> might be lower testing sensitivity in the Vandepitte et al. study [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>], due to different swabbing sites and sample handling, we varied the sensitivity to see if this could ‘reconcile’ the observed patterns (cf. <xref ref-type="fig" rid="pone.0149087.g007">Fig 7</xref>). <xref ref-type="fig" rid="pone.0149087.g008">Fig 8</xref> shows sensitivity and incidence estimates for various recovery rates that were derived from the London-student model. For <italic>γ</italic> = 0.80p.a., the best fitting parameter combination was <italic>λ</italic> = 28%p.a. (95% CI: 22%-38%) with a sensitivity of 56% (95% CI: 47%-63%). The highest relative sensitivity that is consistent with the data is 64%. For <italic>γ</italic><sub><italic>stable</italic>,<italic>max</italic></sub> = 2.06p.a. (i.e., the highest plausible recovery rate in the scenario where all seemingly-persistent infections in the low-risk student group were due to reinfection within a stable partnership), the MLE for the sensitivity is 73% (95% CI: 63%-85%), and the highest plausible sensitivity is 86%.</p>
                <fig id="pone.0149087.g007" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g007</object-id>
                  <label>Fig 7</label>
                  <caption>
                    <title>Incidence rate vs. sensitivity, maximum-likelihood estimate and plausible parameter range, Ugandan sex workers.</title>
                    <p>(A) Initial prevalence. (B) continuously <italic>M</italic>. <italic>genitalium</italic>-positive participants over time. (C) Both data items combined. Thick, black dot: maximum-likelihood estimate (MLE) for the incidence rate (<italic>λ</italic><sub><italic>low</italic></sub> = 28%p.a.) and sensitivity (56%) with recovery rate fixed at <italic>γ</italic> = 0.80p.a. (from London-student data); thin, black contours: equal likelihood; colored areas: white indicates maximum likelihood, red indicated low likelihood; thick, dashed, blue contour: 95% CI of the MLE; thick, red contour: parameter areas where the model is consistent with the empirical data (<italic>α</italic>&lt;0.05).</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g007"/>
                </fig>
                <fig id="pone.0149087.g008" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0149087.g008</object-id>
                  <label>Fig 8</label>
                  <caption>
                    <title>Incidence rate vs. sensitivity, maximum-likelihood estimates and plausible parameter ranges for different recovery rates, Ugandan sex workers.</title>
                    <p>Recovery rates, <italic>γ</italic>, all from London-student data. (A) maximum-likelihood estimate, <italic>γ</italic> = 0.80p.a. (B) upper bound of 95% confidence interval, <italic>γ</italic><sub><italic>UCL</italic></sub> = <italic>γ</italic><sub><italic>stable</italic></sub> = 1.34p.a. (C) highest possible estimate, <italic>γ</italic><sub><italic>max</italic></sub> = 1.84p.a. (D) highest possible estimate when assumed stable partnerships were excluded, <italic>γ</italic><sub><italic>stable</italic>,<italic>max</italic></sub> = 2.06p.a. Thick, black dots: MLEs for incidence rate and sensitivity with fixed recovery rates; thin, black dots: maximum-likelihood estimates (MLEs) for the other recovery rates; thin, black contours: equal likelihood; colored areas: white indicates maximum likelihood, red indicated low likelihood; thick, dashed, blue contour: 95% CI of the MLE; thick, red contour: parameter areas where the model is consistent with the empirical data (<italic>α</italic>&lt;0.05).</p>
                  </caption>
                  <graphic xlink:href="pone.0149087.g008"/>
                </fig>
                <p>Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>] report that “39% of the women who cleared the infection re-gained positive samples again within 3 to 6 months. Some of these recurrent infections could have been persistent infections after a previous false-negative result”; this reported percentage is consistent with our estimate of that study’s sensitivity, and with <italic>γ</italic> = 0.80p.a., the clearance rate which best explains information from both cohort studies. Higher clearance rates combined with higher sensitivities resulted in substantially lower percentages of participants expected showing this pattern, and they were significantly different from the observed figure and, hence, inconsistent with the empirical data.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec023">
              <title>Discussion</title>
              <p>We aimed to improve estimates of the recovery and incidence rates of <italic>M</italic>. <italic>genitalium</italic> from cohort studies. Whilst incidence of infection and rates of antibiotic treatment are dependent upon context and patient behavior, and, hence, may vary markedly between studies, rates of natural clearance are likely to be less variable. Estimation of the clearance rate requires adjusting for other factors that are particular to each study setting.</p>
              <sec id="sec024">
                <title>Factors which impact on clearance rate estimates</title>
                <p>There are several factors that might have affected our estimates.</p>
                <sec id="sec025">
                  <title>Study protocols</title>
                  <p>Oakeshott et al. [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>] used self-taken vaginal swabs and Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>] used staff-taken endocervical swabs. Previous studies suggest that vaginal swab specimens have a higher relative sensitivity than endocervical swab specimens [<xref rid="pone.0149087.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0149087.ref026" ref-type="bibr">26</xref>], and that self-obtained specimens appear to be of similar quality as specimens collected by trained staff [<xref rid="pone.0149087.ref025" ref-type="bibr">25</xref>].</p>
                  <p>Furthermore, Oakeshott et al. [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>] stored samples at lower temperatures than Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>]: -80°C compared with initial storage at 4°C (up to 12 hours) followed by -20°C for more than two years before they were tested for <italic>M</italic>. <italic>genitalium</italic>. Others have reported that DNA degradation might be slower at -80°C than -20°C [<xref rid="pone.0149087.ref027" ref-type="bibr">27</xref>], affecting test sensitivity.</p>
                  <p>Also, other factors, such as the transport media, DNA extraction methods, and PCR test kits might have influenced clearance rate estimates. A thorough assessment as to how exactly these differences might have had an impact on test sensitivity cannot be provided at this time, as they have not been studied or findings have not been published, so far.</p>
                  <p>In light of the discussed protocol differences, we would expect more false-negative test results in the Ugandan study, which would bias parameter estimates towards shorter infection periods because individuals were no longer considered in the published data after their first negative test result. This is corroborated by the agreement of our model results with the frequency of positive-negative-positive results for consecutive time-points, as reported by Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>].</p>
                  <p>A consequence of low relative sensitivities in the Ugandan study is also a higher prevalence than the crude estimate of 14.4%. The highest relative sensitivity estimate compatible with the data is 64%, and the maximum-likelihood estimate is 56%; using these estimates increases the prevalence estimate to 22.5% and 25.7%, respectively. These estimates are consistent with <italic>M</italic>. <italic>genitalium</italic> prevalence estimates for female sex worker populations in developing countries, which were up to 33.5% in Honduras [<xref rid="pone.0149087.ref028" ref-type="bibr">28</xref>] and 26.3% in Ghana and Benin [<xref rid="pone.0149087.ref029" ref-type="bibr">29</xref>].</p>
                </sec>
                <sec id="sec026">
                  <title>Unintentional treatment</title>
                  <p>Neither cohort study provided treatment specifically for <italic>M</italic>. <italic>genitalium</italic>. However, individuals with symptomatic infection might have been treated presumptively, and those who were co-infected with another bacterial STI, particularly <italic>C</italic>. <italic>trachomatis</italic> or <italic>N</italic>. <italic>gonorrhoeae</italic>, were given treatment for the co-infection, which might have cured them of <italic>M</italic>. <italic>genitalium</italic>.</p>
                  <p>Vandepitte et al. reported treating participants with antibiotics, including doxycycline, ciprofloxacin, ceftriaxone, and metronidazole [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>]. Doxycycline has a reported cure rate for <italic>M</italic>. <italic>genitalium</italic> of 17%-94% [<xref rid="pone.0149087.ref030" ref-type="bibr">30</xref>]. A wide range of antibiotics are effective or partly effective against at least some <italic>M</italic>. <italic>genitalium</italic> strains [<xref rid="pone.0149087.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0149087.ref032" ref-type="bibr">32</xref>]. Therefore, treatment for non-STI infections might also have unintentionally cleared <italic>M</italic>. <italic>genitalium</italic>. However, Vandepitte et al. did not detect a higher clearance rate in co-infected participants and reported that they did not detect an association between clearance of <italic>M</italic>. <italic>genitalium</italic> and receipt of antibiotics [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>].</p>
                  <p>Although any effect may have been marginal, we expect that unintentional treatment of <italic>M</italic>. <italic>genitalium</italic> would have been more frequent in the Ugandan study, since there was frequent STI testing and treatment [<xref rid="pone.0149087.ref022" ref-type="bibr">22</xref>]. Furthermore, STI co-infection was more common among Ugandan sex workers than London students, particularly for <italic>N</italic>. <italic>gonorrhoeae</italic>, which occurred in 20.9% of <italic>M</italic>. <italic>genitalium</italic>-positive samples from Ugandan sex workers, whilst no co-infection was detected in the London students. In the London study at baseline 10% of <italic>M</italic>. <italic>genitalium</italic> infections were co-infected with <italic>C</italic>. <italic>trachomatis</italic> compared to 12% in the Ugandan study. Due to the difference in <italic>N</italic>. <italic>gonorrhoeae</italic> co-infection, any effect of unintentional treatment of <italic>M</italic>. <italic>genitalium</italic> will have likely been smaller in the London study.</p>
                </sec>
                <sec id="sec027">
                  <title>Sexual behavior</title>
                  <p>For <italic>C</italic>. <italic>trachomatis</italic>, it is thought that subclinical infections can be transmitted back and forth between partners in a steady sexual relationship without being detected and treated [<xref rid="pone.0149087.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0149087.ref034" ref-type="bibr">34</xref>]. Since <italic>M</italic>. <italic>genitalium</italic> infections are frequently asymptomatic [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0149087.ref035" ref-type="bibr">35</xref>], repeated reinfection within stable partnerships (potentially with several cycles of recovery and reinfection) might be an important cause of apparently-persistent infection within an individual when the interval between testing is relatively long, as in the London study. (The authors reported that genotyping suggested patients testing positive at baseline and follow-up had persistent infections, but these results are also consistent with recovery and reinfection within stable partnerships.) This would bias our estimates towards lower recovery rates (i.e., longer infection duration) and lower incidence estimates.</p>
                </sec>
                <sec id="sec028">
                  <title>Biological differences</title>
                  <p>The London and Uganda cohorts will have differed in their ethnic composition, with the former being more ethnically diverse [<xref rid="pone.0149087.ref020" ref-type="bibr">20</xref>]. People of different ethnicities might have genetic or other biological differences affecting effectiveness of drug treatments [<xref rid="pone.0149087.ref036" ref-type="bibr">36</xref>] or susceptibility to certain infections [<xref rid="pone.0149087.ref037" ref-type="bibr">37</xref>]. Women of African descent might differ from white women in their immune response to bacterial STIs related to PID [<xref rid="pone.0149087.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0149087.ref039" ref-type="bibr">39</xref>]. Finally, the strains of <italic>M</italic>. <italic>genitalium</italic> in the two populations might have had different phenotypes. However, we have no direct evidence for biological differences and the results of our analyses suggest that any such differences are unlikely to have a substantial impact on the two studies.</p>
                  <p>Parts of the Uganda cohort were infected with HIV, but Vandepitte et al. [<xref rid="pone.0149087.ref021" ref-type="bibr">21</xref>] found no association between clearance rates of <italic>M</italic>. <italic>genitalium</italic> and HIV status <italic>per se</italic>. Only those HIV-positive participants with a very low CD4 count (&lt;350/ml) had a slower clearance rate than HIV-negatives. With only 16 such individuals in the cohort, modeling this group explicitly will have had little impact on our estimates.</p>
                </sec>
              </sec>
              <sec id="sec029">
                <title>Interpretation of results</title>
                <p>Infection duration in the London-student data appeared to be long (mean duration 15 months), whereas in the Ugandan sex-worker cohort more than half of the initially <italic>M</italic>. <italic>genitalium</italic>-positive participants appeared to have cleared the infection after three months (<xref ref-type="fig" rid="pone.0149087.g003">Fig 3</xref>).</p>
                <p>We tested the importance of incomplete information by comparing the results of scenarios using different assumptions. Uncertainty in the timing of follow-up testing in the London study makes relatively little difference to estimates, whilst scenarios regarding reinfection result in potentially substantial differences. We identified partnership duration as well as the temporal gap until reinfection within a partnership occurs as critical factors affecting the recovery rate estimate; both are unknown. The basic model for the London data (which ignores partnership duration) might have overestimated the infection duration, but the corresponding MLE also explained recurrent infection in the Ugandan sex workers best. The Ugandan data most likely suggests too-short durations of (untreated) infection because of unintentional treatment of <italic>M</italic>. <italic>genitalium</italic> in co-infected individuals, and probably reduced test sensitivity due to long-term sample storage at -20°C (and, potentially, the choice of transport media or DNA extraction method) and the use of endocervical instead of vaginal swabs. Possibly–although Vandepitte et al. did not detect an effect–unintentional treatment of <italic>M</italic>. <italic>genitalium</italic> in co-infected individuals might have played a minor role.</p>
                <p>Incorporating the effects of (i) reinfection within stable partnerships in the London students and (ii) expected lower test sensitivity in the Ugandan sex-worker study in the model result in a common recovery rate to be plausible. Including all available information, the ‘true’ clearance rate appears to be close to the best estimate for the London-student data. Interestingly, both the London-student and the Ugandan sex-worker data are inconsistent with the findings of Tosh et al. [<xref rid="pone.0149087.ref040" ref-type="bibr">40</xref>], who reported that among adolescent women in the USA “31.3% of untreated <italic>M</italic>. <italic>genitalium</italic> cases had infection lasting over 8 weeks”, suggesting a mean duration of &lt;2 months–i.e., a recovery rate &gt;6p.a., which is outside the plausible ranges of both the London-student and the Ugandan sex-worker model. Long-term storage (up to 2 years, although at -70°C) and treatment of co-infections (15/52 <italic>M</italic>. <italic>genitalium</italic>-positive women tested positive for <italic>C</italic>. <italic>trachomatis</italic> and were treated [<xref rid="pone.0149087.ref040" ref-type="bibr">40</xref>]) might have contributed to this high apparent recovery rate (drug resistance in <italic>M</italic>. <italic>genitalium</italic> may have been lower at the time of the study enrollment, 1999–2006, than more recently [<xref rid="pone.0149087.ref007" ref-type="bibr">7</xref>]), but the difference from the other two studies is not fully understood. An in vitro study also suggests that infection may be prolonged [<xref rid="pone.0149087.ref041" ref-type="bibr">41</xref>].</p>
              </sec>
              <sec id="sec030">
                <title>Future research needs</title>
                <p><italic>M</italic>. <italic>genitalium</italic> is causing increasing concern, particularly regarding if and how it should be managed at the population level, including whether there should be screening or targeted testing [<xref rid="pone.0149087.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0149087.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0149087.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0149087.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0149087.ref017" ref-type="bibr">17</xref>]. Robust parameter estimates are needed for improved understanding of <italic>M</italic>. <italic>genitalium</italic> epidemiology, to inform public health policy, including assessment of cost-effectiveness of intervention strategies.</p>
                <p>To better understand the epidemiology of <italic>M</italic>. <italic>genitalium</italic>, we need robust knowledge about fundamental natural-history parameters [<xref rid="pone.0149087.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0149087.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0149087.ref042" ref-type="bibr">42</xref>], including the duration of untreated infection [<xref rid="pone.0149087.ref010" ref-type="bibr">10</xref>], for reliably identifying groups of individuals that are more likely to contract new infections and/or that are more likely to transmit infection to others [<xref rid="pone.0149087.ref043" ref-type="bibr">43</xref>]. (In Britain, 66% of individuals aged 16–44 years who were infected with Chlamydia had not been tested in the last year [<xref rid="pone.0149087.ref044" ref-type="bibr">44</xref>], making the duration of untreated infection an important determinant of transmission.) There is still considerable uncertainty in rates of sequelae due to <italic>C</italic>. <italic>trachomatis</italic> [<xref rid="pone.0149087.ref018" ref-type="bibr">18</xref>], contributing to continuing uncertainty in cost-effectiveness of screening for that infection [<xref rid="pone.0149087.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0149087.ref030" ref-type="bibr">30</xref>]; we suggest that corresponding knowledge gaps for <italic>M</italic>. <italic>genitalium</italic> should be addressed before decision are taken.</p>
                <p>Future studies would ideally have larger numbers of initially <italic>M</italic>. <italic>genitalium</italic>-positive participants, followed-up sufficiently frequently to detect changes on timescales of a few weeks [<xref rid="pone.0149087.ref040" ref-type="bibr">40</xref>]. Specimens should be collected from the vagina and from the cervix, if possible, as this results in higher sensitivity [<xref rid="pone.0149087.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0149087.ref026" ref-type="bibr">26</xref>].</p>
                <p>Further, ideally, all factors mentioned in the previous section would be controlled for. Collecting more detailed information on sexual behavior and antibiotic use (e.g., Walker et al. [<xref rid="pone.0149087.ref010" ref-type="bibr">10</xref>]) would greatly enhance the value of cohort studies. As we have shown, to estimate the duration of infection, it is important to have information on the incidence (which can lead to recurrent infection) at the individual level, as it is highly heterogeneous: persons in a stable sexual partnership with an infected partner experience a high incidence, typically <italic>greater</italic> than persons who have frequent casual partnerships (but no stable partner), whilst those in an uninfected mutually monogamous partnership have no infection risk. Estimating natural clearance rates requires accounting for antibiotic treatment, including unintentional treatment (e.g., for coinfections).</p>
                <p>Finally, as <italic>M</italic>. <italic>genitalium</italic> is a sexually-transmitted infection which infected women typically acquire from men, it is important to better understand its natural history in males; further studies are required.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <p>TS and PJW thank Pippa Oakeshott and Sarah Kerry for providing additional information. We also thank the anonymous reviewers and academic editors for their helpful comments.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0149087.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Workowski</surname><given-names>KA</given-names></name>, <name><surname>Berman</surname><given-names>SM</given-names></name>. <article-title>Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>; <volume>53</volume>: <fpage>S59</fpage>–<lpage>S63</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir694</pub-id>
<?supplied-pmid 22080270?><pub-id pub-id-type="pmid">22080270</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Taylor-Robinson</surname><given-names>D</given-names></name>, <name><surname>Jensen</surname><given-names>JS</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic>: from chrysalis to multicolored butterfly</article-title>. <source>Clin Microbiol Rev</source>. <year>2011</year>; <volume>24</volume>: <fpage>498</fpage>–<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00006-11</pub-id>
<?supplied-pmid 21734246?><pub-id pub-id-type="pmid">21734246</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Horner</surname><given-names>P</given-names></name>, <name><surname>Thomas</surname><given-names>B</given-names></name>, <name><surname>Gilroy</surname><given-names>CB</given-names></name>, <name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Taylor-Robinson</surname><given-names>D</given-names></name>. <article-title>Role of <italic>Mycoplasma genitalium</italic> and <italic>Ureaplasma urealyticum</italic> in acute and chronic nongonococcal urethritis</article-title>. <source>Clin Infect Dis</source>. <year>2001</year>; <volume>32</volume>: <fpage>995</fpage>–<lpage>1003</lpage>. <?supplied-pmid 11264026?><pub-id pub-id-type="pmid">11264026</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Manhart</surname><given-names>LE</given-names></name>, <name><surname>Critchlow</surname><given-names>CW</given-names></name>, <name><surname>Holmes</surname><given-names>KK</given-names></name>, <name><surname>Dutro</surname><given-names>SM</given-names></name>, <name><surname>Eschenbach</surname><given-names>DA</given-names></name>, <name><surname>Stevens</surname><given-names>CE</given-names></name>, <etal>et al</etal><article-title>Mucopurulent cervicitis and <italic>Mycoplasma genitalium</italic></article-title>. <source>J Infect Dis</source>. <year>2003</year>; <volume>187</volume>: <fpage>650</fpage>–<lpage>657</lpage>. <?supplied-pmid 12599082?><pub-id pub-id-type="pmid">12599082</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Svenstrup</surname><given-names>HF</given-names></name>, <name><surname>Fedder</surname><given-names>J</given-names></name>, <name><surname>Kristoffersen</surname><given-names>SE</given-names></name>, <name><surname>Trolle</surname><given-names>B</given-names></name>, <name><surname>Birkelund</surname><given-names>S</given-names></name>, <name><surname>Christiansen</surname><given-names>G</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic>, <italic>Chlamydia trachomatis</italic>, and tubal factor infertility–a prospective study</article-title>. <source>Fertil Steril</source>. <year>2008</year>; <volume>90</volume>: <fpage>513</fpage>–<lpage>520</lpage>. <?supplied-pmid 17548070?><pub-id pub-id-type="pmid">17548070</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Vandepitte</surname><given-names>J</given-names></name>, <name><surname>Weiss</surname><given-names>HA</given-names></name>, <name><surname>Bukenya</surname><given-names>J</given-names></name>, <name><surname>Kyakuwa</surname><given-names>N</given-names></name>, <name><surname>Muller</surname><given-names>E</given-names></name>, <name><surname>Buvé</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Association between <italic>Mycoplasma genitalium</italic> infection and HIV acquisition among female sex workers in Uganda: evidence from a nested case-control study</article-title>. <source>Sex Transm Infect</source>. <year>2014</year>; <volume>90</volume>: <fpage>545</fpage>–<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1136/sextrans-2013-051467</pub-id>
<?supplied-pmid 24687129?><pub-id pub-id-type="pmid">24687129</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Manhart</surname><given-names>LE</given-names></name>. <article-title>Diagnostic and resistance testing for <italic>Mycoplasma genitalium</italic>: what will it take?</article-title><source>Clin Infect Dis</source>. <year>2014</year>; <volume>59</volume>: <fpage>31</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu224</pub-id>
<?supplied-pmid 24729505?><pub-id pub-id-type="pmid">24729505</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Le Roy</surname><given-names>C</given-names></name>, <name><surname>Pereyre</surname><given-names>S</given-names></name>, <name><surname>Bébéar</surname><given-names>C</given-names></name>. <article-title>Evaluation of two commercial real-time PCR assays for detection of <italic>Mycoplasma genitalium</italic> in urogenital specimens</article-title>. <source>J Clin Microbiol</source>. <year>2014</year>; <volume>52</volume>: <fpage>971</fpage>–<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.02567-13</pub-id>
<?supplied-pmid 24371239?><pub-id pub-id-type="pmid">24371239</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Taylor-Robinson</surname><given-names>D</given-names></name>. <article-title>Diagnosis and antimicrobial treatment of <italic>Mycoplasma genitalium</italic> infection: sobering thoughts</article-title>. <source>Expert Rev Anti Infect Ther</source>. <year>2014</year>; <volume>12</volume>: <fpage>715</fpage>–<lpage>722</lpage>. <pub-id pub-id-type="doi">10.1586/14787210.2014.919220</pub-id>
<?supplied-pmid 24834454?><pub-id pub-id-type="pmid">24834454</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>J</given-names></name>, <name><surname>Fairley</surname><given-names>CK</given-names></name>, <name><surname>Bradshaw</surname><given-names>CS</given-names></name>, <name><surname>Tabrizi</surname><given-names>SN</given-names></name>, <name><surname>Twin</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>MY</given-names></name>, <etal>et al</etal><article-title><italic>Mycoplasma genitalium</italic>. Incidence, Organism Load, and Treatment Failure in a Cohort of Young Australian Women</article-title>. <source>Clin Infect Dis</source>. <year>2013</year>; <volume>56</volume>:<fpage>1094</fpage>–<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cis1210</pub-id>
<?supplied-pmid 23300236?><pub-id pub-id-type="pmid">23300236</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Manhart</surname><given-names>LE</given-names></name>, <name><surname>Gillespie</surname><given-names>CW</given-names></name>, <name><surname>Lowens</surname><given-names>MS</given-names></name>, <name><surname>Khosropour</surname><given-names>CM</given-names></name>, <name><surname>Colombara</surname><given-names>DV</given-names></name>, <name><surname>Golden</surname><given-names>MR</given-names></name>, <etal>et al</etal><article-title>Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial</article-title>. <source>Clin Infect Dis</source>. <year>2013</year>; <volume>56</volume>: <fpage>934</fpage>–<lpage>942</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cis1022</pub-id>
<?supplied-pmid 23223595?><pub-id pub-id-type="pmid">23223595</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Mena</surname><given-names>LA</given-names></name>, <name><surname>Mroczkowski</surname><given-names>TF</given-names></name>, <name><surname>Nsuami</surname><given-names>M</given-names></name>, <name><surname>Martin</surname><given-names>DH</given-names></name>. <article-title>A randomized comparison of azithromycin and doxycycline for the treatment of <italic>Mycoplasma genitalium</italic>-positive urethritis in men</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>; <volume>48</volume>: <fpage>1649</fpage>–<lpage>1654</lpage>. <pub-id pub-id-type="doi">10.1086/599033</pub-id>
<?supplied-pmid 19438399?><pub-id pub-id-type="pmid">19438399</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Salado-Rasmussen</surname><given-names>K</given-names></name>, <name><surname>Jensen</surname><given-names>JS</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic> testing pattern and macrolide resistance: a Danish nationwide retrospective survey</article-title>. <source>Clin Infect Dis</source>. <year>2014</year>; <volume>59</volume>: <fpage>24</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu217</pub-id>
<?supplied-pmid 24729494?><pub-id pub-id-type="pmid">24729494</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>JS</given-names></name>, <name><surname>Bradshaw</surname><given-names>CD</given-names></name>, <name><surname>Tabrizi</surname><given-names>SN</given-names></name>, <name><surname>Fairley</surname><given-names>CK</given-names></name>, <name><surname>Hamasuna</surname><given-names>R</given-names></name>. <article-title>Azithromycin treatment failure in <italic>Mycoplasma genitalium</italic>-positive patients with nongonococcal urethritis is associated with induced macrolide resistance</article-title>. <source>Clin Infect Dis</source>. <year>2008</year>; <volume>47</volume>: <fpage>1546</fpage>–<lpage>1553</lpage>. <pub-id pub-id-type="doi">10.1086/593188</pub-id>
<?supplied-pmid 18990060?><pub-id pub-id-type="pmid">18990060</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Pond</surname><given-names>MJ</given-names></name>, <name><surname>Nori</surname><given-names>AV</given-names></name>, <name><surname>Witney</surname><given-names>AA</given-names></name>, <name><surname>Lopeman</surname><given-names>RC</given-names></name>, <name><surname>Butcher</surname><given-names>PD</given-names></name>, <name><surname>Sadiq</surname><given-names>ST</given-names></name>. <article-title>High prevalence of antibiotic-resistant <italic>Mycoplasma genitalium</italic> in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options</article-title>. <source>Clin Infect Dis</source>. <year>2014</year>; <volume>58</volume>: <fpage>631</fpage>–<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit752</pub-id>
<?supplied-pmid 24280088?><pub-id pub-id-type="pmid">24280088</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Horner</surname><given-names>P</given-names></name>, <name><surname>Blee</surname><given-names>K</given-names></name>, <name><surname>Adams</surname><given-names>E</given-names></name>. <article-title>Time to manage <italic>Mycoplasma genitalium</italic> as an STI: but not with azithromycin 1g!</article-title><source>Curr Opin Infect Dis</source>. <year>2014</year>, <volume>27</volume>: <fpage>68</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1097/QCO.0000000000000030</pub-id>
<?supplied-pmid 24322592?><pub-id pub-id-type="pmid">24322592</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Daley</surname><given-names>GM</given-names></name>, <name><surname>Russell</surname><given-names>DB</given-names></name>, <name><surname>Tabrizi</surname><given-names>SN</given-names></name>, <name><surname>McBride</surname><given-names>J</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic>: a review</article-title>. <source>Int J STD AIDS</source>. <year>2014</year>; <volume>25</volume>: <fpage>475</fpage>–<lpage>487</lpage>. <?supplied-pmid 24517928?><pub-id pub-id-type="pmid">24517928</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Haggerty</surname><given-names>CL</given-names></name>, <name><surname>Gottlieb</surname><given-names>SL</given-names></name>, <name><surname>Taylor</surname><given-names>BD</given-names></name>, <name><surname>Low</surname><given-names>N</given-names></name>, <article-title>Xu Fujie, Ness RB. Risk of sequelae after <italic>Chlamydia trachomatis</italic> genital infection in women</article-title>. <source>J Infect Dis</source>. <year>2010</year>; <volume>201</volume>(<issue>S2</issue>): <fpage>S134</fpage>–<lpage>S155</lpage>.<pub-id pub-id-type="pmid">20470050</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>B</given-names></name>, <name><surname>Anderson</surname><given-names>S-J</given-names></name>, <name><surname>Turner</surname><given-names>KME</given-names></name>, <name><surname>Ward</surname><given-names>H</given-names></name>. <article-title>How robust are the natural history parameters used in chlamydia transmission dynamic models? A systematic review</article-title>. <source>Theor Biol Med Model</source>. <year>2014</year>; <volume>11</volume>: <fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1742-4682-11-8</pub-id><?supplied-pmid 24476335?><pub-id pub-id-type="pmid">24476335</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Oakeshott</surname><given-names>P</given-names></name>, <name><surname>Aghaizu</surname><given-names>A</given-names></name>, <name><surname>Hay</surname><given-names>P</given-names></name>, <name><surname>Reid</surname><given-names>F</given-names></name>, <name><surname>Kerry</surname><given-names>S</given-names></name>, <name><surname>Atherton</surname><given-names>H</given-names></name>, <etal>et al</etal><article-title>Is <italic>Mycoplasma genitalium</italic> in women the ‘new chlamydia?’ A community-based prospective cohort study</article-title>. <source>Clin Infect Dis</source>. <year>2010</year>; <volume>51</volume>: <fpage>1160</fpage>–<lpage>1166</lpage>. <pub-id pub-id-type="doi">10.1086/656739</pub-id>
<?supplied-pmid 20942656?><pub-id pub-id-type="pmid">20942656</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Vandepitte</surname><given-names>J</given-names></name>, <name><surname>Weiss</surname><given-names>HA</given-names></name>, <name><surname>Kyakuwa</surname><given-names>N</given-names></name>, <name><surname>Nakubulwa</surname><given-names>S</given-names></name>, <name><surname>Muller</surname><given-names>E</given-names></name>, <name><surname>Buvé</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Natural history of <italic>Mycoplasma genitalium</italic> infection in a cohort of female sex workers in Kampala, Uganda</article-title>. <source>Sex Transm Dis</source>. <year>2013</year>; <volume>40</volume>: <fpage>422</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1097/OLQ.0b013e31828bfccf</pub-id>
<?supplied-pmid 23588134?><pub-id pub-id-type="pmid">23588134</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Vandepitte</surname><given-names>J</given-names></name>, <name><surname>Bukenya</surname><given-names>J</given-names></name>, <name><surname>Weiss</surname><given-names>HA</given-names></name>, <name><surname>Nakubulwa</surname><given-names>S</given-names></name>, <name><surname>Francis</surname><given-names>SC</given-names></name>, <name><surname>Hughes</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behaviour in Kampala, Uganda</article-title>. <source>Sex Transm Dis</source>. <year>2011</year>; <volume>38</volume>: <fpage>316</fpage>–<lpage>323</lpage>. <?supplied-pmid 23330152?><pub-id pub-id-type="pmid">23330152</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Vandepitte</surname><given-names>J</given-names></name>, <name><surname>Muller</surname><given-names>E</given-names></name>, <name><surname>Bukenya</surname><given-names>J</given-names></name>, <name><surname>Nakubulwa</surname><given-names>S</given-names></name>, <name><surname>Kyakuwa</surname><given-names>N</given-names></name>, <name><surname>Buvé</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Prevalence and correlates of <italic>Mycoplasma genitalium</italic> infection among female sex workers in Kampala, Uganda</article-title>. <source>J Infect Dis</source>. <year>2012</year>; <volume>205</volume>: <fpage>289</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jir733</pub-id>
<?supplied-pmid 22102734?><pub-id pub-id-type="pmid">22102734</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Manhart</surname><given-names>LE</given-names></name>, <name><surname>Kay</surname><given-names>N</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic>: is it a sexually transmitted pathogen?</article-title><source>Curr Infect Dis Rep</source>. <year>2010</year>; <volume>12</volume>: <fpage>306</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1007/s11908-010-0114-3</pub-id>
<?supplied-pmid 21308546?><pub-id pub-id-type="pmid">21308546</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Wroblewski</surname><given-names>JKH</given-names></name>, <name><surname>Manhart</surname><given-names>LE</given-names></name>, <name><surname>Dickey</surname><given-names>KA</given-names></name>, <name><surname>Hudspeth</surname><given-names>MK</given-names></name>, <name><surname>Totten</surname><given-names>PA</given-names></name>. <article-title>Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium</article-title>. <source>J Clin Microbiol</source>. <year>2006</year>; <volume>44</volume>: <fpage>3306</fpage>–<lpage>3312</lpage>. <?supplied-pmid 16954265?><pub-id pub-id-type="pmid">16954265</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Lillis</surname><given-names>RA</given-names></name>, <name><surname>Nsuami</surname><given-names>MJ</given-names></name>, <name><surname>Myers</surname><given-names>L</given-names></name>, <name><surname>Martin</surname><given-names>DH</given-names></name>. <article-title>Utility of urine, vaginal, cervical, and rectal specimens for detection of Mycoplasma genitalium</article-title>. <source>J Clin Microbiol</source>. <year>2011</year>; <volume>49</volume>: <fpage>1990</fpage>–<lpage>1992</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00129-11</pub-id>
<?supplied-pmid 21411587?><pub-id pub-id-type="pmid">21411587</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Carlsen</surname><given-names>K</given-names></name>, <name><surname>Jensen</surname><given-names>J</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic> PCR: does freezing of specimens affect sensitivity?</article-title><source>J Clin Microbiol</source>. <year>2010</year>; <volume>48</volume>: <fpage>3624</fpage>–<lpage>3627</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00232-10</pub-id>
<?supplied-pmid 20720022?><pub-id pub-id-type="pmid">20720022</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Johnston</surname><given-names>LG</given-names></name>, <name><surname>Paz</surname><given-names>Bailey G</given-names></name>, <name><surname>Morales-Miranda</surname><given-names>S</given-names></name>, <name><surname>Morgan</surname><given-names>M</given-names></name>, <name><surname>Alvarez</surname><given-names>B</given-names></name>, <name><surname>Hickman</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>High prevalence of <italic>M</italic>. <italic>genitalium</italic> among female sex workers in Honduras: implications for the spread of HIV and other sexually transmitted infections</article-title>. <source>Int J STD AIDS</source>. <year>2012</year>; <volume>23</volume>: <fpage>5</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1258/ijsa.2009.009446</pub-id>
<?supplied-pmid 22362680?><pub-id pub-id-type="pmid">22362680</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Pépin</surname><given-names>J</given-names></name>, <name><surname>Labbé A-</surname><given-names>C</given-names></name>, <name><surname>Khonde</surname><given-names>N</given-names></name>, <name><surname>Deslandes</surname><given-names>S</given-names></name>, <name><surname>Alary</surname><given-names>M</given-names></name>, <name><surname>Dzokoto</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title><italic>Mycoplasma genitalium</italic>: an organism commonly associated with cervicitis among west African sex workers</article-title>. <source>Sex Transm Infect</source>. <year>2005</year>; <volume>81</volume>: <fpage>67</fpage>–<lpage>72</lpage>. <?supplied-pmid 15681727?><pub-id pub-id-type="pmid">15681727</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Manhart</surname><given-names>LE</given-names></name>, <name><surname>Broad</surname><given-names>JM</given-names></name>, <name><surname>Golden</surname><given-names>MR</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic>: should we treat and how?</article-title><source>Clin Infect Dis</source>. <year>2011</year>; <volume>53</volume>: <fpage>S129</fpage>–<lpage>S142</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir702</pub-id>
<?supplied-pmid 22080266?><pub-id pub-id-type="pmid">22080266</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Hamasuna</surname><given-names>R</given-names></name>, <name><surname>Osada</surname><given-names>Y</given-names></name>, <name><surname>Jensen</surname><given-names>JS</given-names></name>. <article-title>Antibiotic susceptibility testing of <italic>Mycoplasma genitalium</italic> by TaqMan 5' nuclease real-time PCR</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>; <volume>49</volume>: <fpage>4993</fpage>–<lpage>4998</lpage>. <?supplied-pmid 16304163?><pub-id pub-id-type="pmid">16304163</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>LB</given-names></name>, <name><surname>Crabb</surname><given-names>D</given-names></name>, <name><surname>Searcey</surname><given-names>K</given-names></name>, <name><surname>Kempf</surname><given-names>MC</given-names></name>. <article-title>Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against <italic>Mycoplasma</italic> spp</article-title>. <source>J Antimicrob Chemother</source>. <year>2000</year>; <volume>45</volume>: <fpage>29</fpage>–<lpage>33</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0149087.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Hosenfeld</surname><given-names>CB</given-names></name>, <name><surname>Workowski</surname><given-names>KA</given-names></name>, <name><surname>Berman</surname><given-names>S</given-names></name>, <name><surname>Zaidi</surname><given-names>A</given-names></name>, <name><surname>Dyson</surname><given-names>J</given-names></name>, <name><surname>Mosure</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature</article-title>. <source>Sex Transm Dis</source>. <year>2009</year>; <volume>36</volume>: <fpage>478</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1097/OLQ.0b013e3181a2a933</pub-id>
<?supplied-pmid 19617871?><pub-id pub-id-type="pmid">19617871</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Golden</surname><given-names>M</given-names></name>, <name><surname>Whittington</surname><given-names>W</given-names></name>. <article-title>Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection</article-title>. <source>N Engl J Med</source>. <year>2005</year>; <volume>352</volume>: <fpage>676</fpage>–<lpage>685</lpage>. <?supplied-pmid 15716561?><pub-id pub-id-type="pmid">15716561</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Anagrius</surname><given-names>C</given-names></name>, <name><surname>Loré</surname><given-names>B</given-names></name>, <name><surname>Jensen</surname><given-names>JS</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic>: prevalence, clinical significance, and transmission</article-title>. <source>Sex Transm Infect</source>. <year>2005</year>; <volume>81</volume>: <fpage>458</fpage>–<lpage>462</lpage>. <?supplied-pmid 16326846?><pub-id pub-id-type="pmid">16326846</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Burroughs</surname><given-names>V</given-names></name>, <name><surname>Maxey</surname><given-names>R</given-names></name>, <name><surname>Levy</surname><given-names>R</given-names></name>. <article-title>Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment</article-title>. <source>J Natl Med Assoc</source>. <year>2002</year>; <volume>94</volume>: <fpage>1</fpage>–<lpage>26</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0149087.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Stead</surname><given-names>W</given-names></name>, <name><surname>Senner</surname><given-names>J</given-names></name>, <name><surname>Reddick</surname><given-names>W</given-names></name>, <name><surname>Lofgren</surname><given-names>JP</given-names></name>. <article-title>Racial differences in susceptibility to infection by <italic>Mycobacterium tuberculosis</italic></article-title>. <source>N Engl J Med</source>. <year>1990</year>; <volume>322</volume>: <fpage>422</fpage>–<lpage>427</lpage>. <?supplied-pmid 2300105?><pub-id pub-id-type="pmid">2300105</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>BD</given-names></name>, <name><surname>Darville</surname><given-names>T</given-names></name>, <name><surname>Ferrell</surname><given-names>RE</given-names></name>, <name><surname>Ness</surname><given-names>RB</given-names></name>, <name><surname>Haggerty</surname><given-names>CL</given-names></name>. <article-title>Racial variation in toll-like receptor variants among women with pelvic inflammatory disease</article-title>. <source>J Infect Dis</source>. <year>2013</year>; <volume>207</volume>: <fpage>940</fpage>–<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis922</pub-id>
<?supplied-pmid 23255565?><pub-id pub-id-type="pmid">23255565</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>BD</given-names></name>, <name><surname>Darville</surname><given-names>T</given-names></name>, <name><surname>Ferrell</surname><given-names>RE</given-names></name>, <name><surname>Kammerer</surname><given-names>CM</given-names></name>, <name><surname>Ness</surname><given-names>RB</given-names></name>, <name><surname>Haggerty</surname><given-names>CL</given-names></name>. <article-title>Variants in toll-like receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease</article-title>. <source>J Infect Dis</source>. <year>2012</year>; <volume>205</volume>:<fpage>603</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jir822</pub-id>
<?supplied-pmid 22238472?><pub-id pub-id-type="pmid">22238472</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Tosh</surname><given-names>AK</given-names></name>, <name><surname>Van der Pol</surname><given-names>B</given-names></name>, <name><surname>Fortenberry</surname><given-names>J</given-names></name>, <name><surname>Williams</surname><given-names>JA</given-names></name>, <name><surname>Katz</surname><given-names>BP</given-names></name>, <name><surname>Batteiger</surname><given-names>BE</given-names></name>, <etal>et al</etal><article-title><italic>Mycoplasma genitalium</italic> among adolescent women and their partners</article-title>. <source>J Adolesc Health</source>. <year>2007</year>; <volume>40</volume>: <fpage>412</fpage>–<lpage>417</lpage>. <?supplied-pmid 17448398?><pub-id pub-id-type="pmid">17448398</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>McGowin</surname><given-names>CL</given-names></name>, <name><surname>Annan</surname><given-names>RS</given-names></name>, <name><surname>Quayle</surname><given-names>AJ</given-names></name>, <name><surname>Greene</surname><given-names>SJ</given-names></name>, <name><surname>Ma</surname><given-names>L</given-names></name>, <name><surname>Mancuso</surname><given-names>MM</given-names></name>, <etal>et al</etal><article-title>Persistent <italic>Mycoplasma genitalium</italic> infection of human endocervical epithelial cells elicits chronic inflammatory cytokine secretion</article-title>. <source>Infect Immun</source>. <year>2012</year>; <volume>80</volume>: <fpage>3842</fpage>–<lpage>3849</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00819-12</pub-id>
<?supplied-pmid 22907815?><pub-id pub-id-type="pmid">22907815</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Manhart</surname><given-names>LE</given-names></name>, <name><surname>McClelland</surname><given-names>RS</given-names></name>. <article-title><italic>Mycoplasma genitalium</italic> Infection in Sub-Saharan Africa: How Big Is the Problem?</article-title><source>Sex Transm Dis</source>. <year>2013</year>; <volume>40</volume>: <fpage>429</fpage>–<lpage>430</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0149087.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Smieszek</surname><given-names>T</given-names></name>, <name><surname>Salathé</surname><given-names>M</given-names></name>. <article-title>A low-cost method to assess the epidemiological importance of individuals in controlling infectious disease outbreaks</article-title>. <source>BMC Med</source>. <year>2013</year>; <volume>11</volume>: <fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-11-35</pub-id><?supplied-pmid 23402633?><pub-id pub-id-type="pmid">23402633</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0149087.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Sonnenberg</surname><given-names>P</given-names></name>, <name><surname>Clifton</surname><given-names>S</given-names></name>, <name><surname>Beddows</surname><given-names>S</given-names></name>, <name><surname>Field</surname><given-names>N</given-names></name>, <name><surname>Soldan</surname><given-names>K</given-names></name>, <name><surname>Tanton</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)</article-title>. <source>Lancet</source>. <year>2013</year>; <volume>382</volume>: <fpage>1795</fpage>–<lpage>1806</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)61947-9</pub-id>
<?supplied-pmid 24286785?><pub-id pub-id-type="pmid">24286785</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
